相关实验视频

Updated: Jun 26, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

在非小细胞肺癌中使用RAF和MEK抑制剂

Christos Adamopoulos^1,2, Kostas A Papavassiliou³, Poulikos I Poulikakos²

¹Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.

International journal of molecular sciences

|May 11, 2024

概括

使用RAF和MEK抑制剂治疗BRAFV600E突变非小细胞肺癌 (NSCLC) 的向治疗显示出有前途. 获得的耐药性仍然是一个挑战,推动开发新的抑制剂以改善患者的治疗结果.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

非小细胞肺癌 (NSCLC) 仍然是全球主要的健康问题.
受体氨酸激酶-RAS-线原激活蛋白激酶 (RTK-RAS-MAPK) 途径在NSCLC的发病过程中至关重要.
与KRAS相比,BRAF中的激活突变在NSCLC中是较不常见的驱动因素.

研究的目的:

在NSCLC管理中审查RAF和MEK抑制的现状.
探索RAF-MEK抑制剂在BRAFV600E突变NSCLC中的治疗潜力和挑战.
突出新型RAF和MEK抑制剂的发展.

主要方法:

关于RAF和MEK抑制剂在NSCLC中的临床前和临床研究的文献综述.
对批准的RAF-MEK抑制剂组合的监管批准和临床试验数据的分析.
检查对RAF-MEK抑制剂获得耐药性的机制.

主要成果:

RAF-MEK抑制剂组合 (达布拉费尼布-特拉美丁尼布,恩科拉费尼布-比尼米丁尼布) 已被批准用于治疗BRAFV600E突变NSCLC.
这些向疗法代表了突破,但受到获得的耐药性限制.
新的RAF和MEK抑制剂正在研究中,其简介得到了改进.

结论:

RAF和MEK抑制剂为NSCLC患者的一个子集提供了有针对性的方法.
克服获得的耐药性对于最大限度地提高这些药物的临床益处至关重要.
对新型抑制剂的持续研究对未来的NSCLC治疗策略有希望.

关键词:

BRAF 抑制剂的使用这就是BRAFV600E.通过MAPK路径.作为MEK抑制剂的使用.肺癌是一种肺癌.非小细胞肺癌的肺癌.有针对性的治疗方法.

更多相关视频

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

MAPK Signaling Cascades

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...